---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021425"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:34:33.153331+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M

## Summary
- At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.
- CRS for JANX007 only Grade 1/2 and transient; doses up to 3 mg with no MTD reached.
- JANX008: One NSCLC subject with confirmed PR (100% lung target reduction, liver mets eliminated); no CRS or TRAEs.
- 11 heavily pre-treated subjects enrolled across four tumor types in JANX008; no SAEs or DLTs.
- Preliminary cash, equivalents, and short-term investments ~$338.2M as of Jan 31, 2024 (incl. $0.8M restricted).

## SEC filing metadata
- accession: 0000950170-24-021425
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024021425/0000950170-24-021425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024021425/janx-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021425
- JSON: https://secwatch.observer/filing/0000950170-24-021425.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.